Coherus Oncology (CHRS) Gross Margin (2019 - 2026)

Coherus Oncology has disclosed Gross Margin across 8 years of filings, most recently posting 70.35% for Q2 2026.

• In Q2 2026, Gross Margin rose 346.0% year-over-year to 70.35%; the TTM figure through Jun 2026 stood at 68.94% (up 537.0% YoY), while the FY2025 annual figure was 67.24%, up 31.0% from the prior year.
• Gross Margin came in at 70.35% for Q2 2026 at Coherus Oncology, up from 69.02% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 84.41% in Q1 2022 to a low of 7.6% in Q4 2023.
• Average Gross Margin over 5 years is 59.62%, with a median of 65.99% recorded in 2025.
• Year-over-year, Gross Margin plunged 6108 bps in 2023 and surged 5684 bps in 2024.
• Over 5 years, Gross Margin stood at 68.68% in 2022, then slumped by 89 bps to 7.6% in 2023, then surged by 748 bps to 64.44% in 2024, then grew by 6 bps to 68.27% in 2025, then gained by 3 bps to 70.35% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 70.35% in Q2 2026, 69.02% in Q1 2026, and 68.27% in Q4 2025.